Eli Lilly & Co.'s Trulicity and Merck & Co.'s Keytruda could face Medicare drug price negotiations by 2028, according to a study published Monday analyzing the federal government’s new drug pricing authority.
From 2026 to 2028, Medicare beneficiaries could see new prices from the Centers for Medicare & Medicaid Services for 38 Part D and Part B drugs, according to the analysis published in the Journal of Managed Care & Specialty Pharmacy. The study, conducted by the West Health Policy Center’s Sean Dickson and University of California, San Diego, Associate Professor Inmaculada Hernandez, is what analysts say is one of ...
To read the full article log in.
Read Full Story: https://news.google.com/rss/articles/CBMidWh0dHBzOi8vbmV3cy5ibG9vbWJlcmdsYXcu...
A La Habra-based provider of positron emission tomography scan services has agreed to pay more than $8.3 million to resolve allegations it violated the False Claims Act by offering improper payment...